Table 2.
Pharmacological assessment of IPSCs using TPMPA, NO-711, zolpidem, and clonazepam
| Control (n)/Fmr1−/y (n) | TPMPA efficacy (mean ± SEM %Δ mIPSC amplitude) | NO-711 enhancement (mean ± SEM %) | Zolpidem enhancement (mean ± SEM %) | Clonazepam enhancement (mean ± SEM %) |
|---|---|---|---|---|
| P10 | −13.8 ± 2.1 (5)/−27.4 ± 3.4 (7) | 2.8 ± 6.1 (9)/5.0 ± 10.6 (4) | 6.4 ± 9.1 (5)/16.2 ± 2.7 (6) | 54.8 ± 7.8 (11)/13.8 ± 6.3 (10) |
| p = 0.012 | p = 0.911 | p = 0.230 | p = 0.0005 | |
| P14 | −14.7 ± 4.4 (5)/−15.7 ± 2.0 (7) | ND/ND | 15.0 ± 4.0 (6)/3.0 ± 0.5 (6) | 45.2 ± 7.0 (8)/30.5 ± 3.9 (7) |
| p = 0.834 | p = 0.100 | p = 0.102 | ||
| P16 | −18.4 ± 3.4 (5)/−22.2 ± 2.8 (5) | ND/ND | 21.6 ± 2.3 (5)/1.0 ± 11.6 (7) | 34.9 ± 4.2 (5)/43.1 ± 12.0 (8) |
| p = 0.401 | p = 0.045 | p = 0.490 | ||
| P21 | −12.2 ± 2.0 (5)/−27.6 ± 4.7 (6) | 27.9 ± 10.8 (5)/57.5 ± 5.2 (7) | 50.3 ± 1.7 (8)/11.3 ± 4.5 (8) | 2.1 ± 4.8 (12)/ 20.6 ± 7.3 (14) |
| p = 0.018 | p = 0.022 | p = 0.027 | p = 0.048 |
Pharmacological assessment of IPSCs using TPMPA, NO-711, zolpidem, and clonazepam. TPMPA efficacy is defined as the mean ± SEM of the change in mIPSC amplitude in the presence of 100 μm TPMPA. NO-711 enhancement values (defined as the percentage change in decay constant with drug application) are given for control (roman text) and Fmr1−/y (bold text) at each of the ages tested. Zolpidem and clonazepam enhancement values (defined as the percentage change in decay constant with drug application) are given for wild-type (roman text) and Fmr1−/y (bold text) at each of the ages tested. The number of cells in each group is indicated in parentheses. A Student's two-tailed t test was performed for all conditions. The p values are listed below the averaged value, and p < 0.05 are shown in bold. ND, Not determined.